Skip to content

DynaMed Plus – 2018 ‘Best of’ Research

bestof2018DynaMed Plus' editorial team systematically reviews newly published health sciences literature in order to ensure that the best available evidence is integrated into DynaMed Plus articles.  Last year, the DynaMed team reviewed more than 20,000 articles and added used information from more than 9,000 of these articles to update articles in DynaMed Plus.  In their 2018 Year in Review, DynaMed's editorial team present the five most important articles from 2018:
  1. Antihypertensive treatment for low-risk patients with mild hypertension does not appear to be beneficial.  Sheppard, J. P., Stevens, S., Stevens, R., Martin, U., Mant, J., Hobbs, F. R., & McManus, R. J. (2018). Benefits and Harms of Antihypertensive Treatment in Low-Risk Patients With Mild Hypertension. JAMA internal medicine, 178(12), 1626-1634.
  2. Aspirin for primary prevention does not reduce vascular events in adults aged ≥ 70 years and may increase rates of death and major bleeding.   McNeil, J. J., Wolfe, R., Woods, R. L., Tonkin, A. M., Donnan, G. A., Nelson, M. R., ... & Shah, R. C. (2018). Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. New England Journal of Medicine, 379(16), 1509-1518.
  3. Vitamin D plus calcium supplementation might not reduce the risk of hip fracture in unselected community-dwelling adults > 50 years old.  Zhao, J. G., Zeng, X. T., Wang, J., & Liu, L. (2017). Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults: a systematic review and meta-analysis. Jama, 318(24), 2466-2482.
  4. Could elective inductions at 39 weeks in low-risk nulliparous women help neonates ARRIVE more quickly and more safely?  Grobman, W. A., Rice, M. M., Reddy, U. M., Tita, A. T., Silver, R. M., Mallett, G., ... & Rouse, D. J. (2018). Labor induction versus expectant management in low-risk nulliparous women. New England Journal of Medicine, 379(6), 513-523.
  5. As-needed budesonide/formoterol for mild persistent asthma may prevent serious exacerbations as well as twice-daily maintenance budesonide.   Bateman, E. D., Reddel, H. K., O’byrne, P. M., Barnes, P. J., Zhong, N., Keen, C., ... & FitzGerald, J. M. (2018). As-needed budesonide–formoterol versus maintenance budesonide in mild asthma. New England Journal of Medicine, 378(20), 1877-1887.
Print Friendly, PDF & Email